-
Innovation Ranking
Innovation Ranking – Keurig Dr Pepper Inc
Keurig Dr Pepper Inc (KDP) is a manufacturer and distributor of non-alcoholic beverages. The company’s product portfolio includes coffees, carbonated soft drinks, ready-to-drink tea, water, juices, juice drinks and mixers, among others. KDP markets its products under brands such as Dr Pepper, Snapple, Keurig, Green Mountain, Donut Shop, Van Houtte, REVV, and Mott's. The company serves various bottlers, distributors, and retailers, including hypermarkets, supermarkets, mass merchandisers, e-commerce retailers, club stores, office superstores, fountains, vending machines, convenience stores, grocery and drug...
-
Innovation Ranking
Innovation Ranking – Dr. Reddy’s Laboratories Ltd
Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars and proprietary products. The company’s generic products are indicated for the treatment of gastrointestinal disorders, various cancer types, cardiovascular diseases, pain, central nervous system disorders, infectious diseases, and pediatric diseases. The company also develops and markets generic biosimilar products. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crofelemer DR in Cholera
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crofelemer DR in Cholera report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crofelemer DR in Cholera Drug Details: Crofelemer (Fulyzaq, Mytesi) is an anti...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crofelemer DR in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crofelemer DR in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crofelemer DR in Irritable Bowel Syndrome Drug Details: Crofelemer (Fulyzaq,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Hematological Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DR-0201 in Hematological Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Hematological Tumor Drug Details: DR-0201 is under development for the...
-
Thematic Analysis
NewMedical Devices M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Medical Devices Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin DR in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin DR in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin DR in Sickle Cell Disease Drug Details: Rifaximin delayed-release...
-
Sector Analysis
NewReady-to-Drink (RTD) Beverages Market Trends and Analysis by Product Type, Pack Size, Pack Material and Segment Forecast to 2028
Accessing the in-depth insights from the ‘Ready-to-Drink (RTD) Beverages’ report can help: Understand the current and future state of the market, allowing businesses to make informed decisions about market entry, product development, and investments Identify competitors' capabilities to stay ahead in the market Identify segments and get an understanding of various stakeholders across different stages of the entire value chain Anticipate changes in demand and adjust the business development strategies Identify potential regions and countries for growth opportunities How is our ‘Ready-to-Drink (RTD) Beverages report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Graves' Ophthalmopathy Drug Details: Aflibercept (Eylea / Eylea HD) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aflibercept in Retinopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aflibercept in Retinopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aflibercept in Retinopathy Drug Details: Aflibercept (Eylea / Eylea HD) is a recombinant...